Non-small cell lung cancer (NSCLC) is one of the leading causes of death globally. Alterations in epidermal growth factor receptor gene (EGFR) are among the most common driver mutations in NSCLC. EGFR mutations are present in 16-19% of Caucasian patients with NSCLC, whereas that in Asian patients with NSCLC adenocarcinoma is approximately 37-41%. Patients with EGFR exon 20 insertion (ex20-ins) mutations have worse survival than patients with EGFR exon 19 deletions or L858R mutations. Essentially, NSCLC with ex20-ins is resistant to conventional EGFR tyrosine kinase inhibitors (TKIs).

Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity, binds to each receptor’s extracellular domain, bypassing resistance at the TKI binding site. Given the unmet need in NSCLC with ex20-ins, recent clinical trials demonstrated that amivantamab yielded robust and durable responses with tolerable safety in patients with the disease after progression on platinum-based chemotherapy.

On 10-Feb 2023, a hybrid symposium titled “Optimizing Treatment for EGFR Exon 20 insertion Patient After Platinum-based Chemotherapy” was successfully organised. In the event, Dr. Kirsty Wai Chung Lee of the The Chinese University of Hong Kong highlighted the update in clinical diagnosis of NSCLC and the pathophysiology of NSCLC with ex20-ins. Moreover, Prof. Byoung Chui Cho of the Yonsei University College of Medicine presented the pharmacology and clinical efficacy of amivantamab. He further his experience on managing NSCLC with ex20-ins with amivantamab and discussed the treatment outcomes. The lectures were followed by fruitful discussion between the keynote speakers and audience.

Dr. Lee highlighted the updates in NSCLC precision medicine

The clinical performance of amivantamab in NSCLC with ex20-ins was evaluated

Prof. Cho presented the unmet need in management of NSCLC with ex20-ins

Clinical case shared by Prof Cho on the treatment with amivantamab in NSCLC with ex20-ins